(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Sponsor
Ruijin Hospital
Study ID
NCT05923502
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Peripheral T Cell Lymphoma
  • Richter Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Duvelisib — DRUG
    This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.

Study Details

This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.

Key Dates

First listed
Jun 28, 2023
Start date
Oct 20, 2023
Status verified
Oct 2023
Primary completion
Nov 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: All enrolled patients.
    All patient who signed the consent form for participation to the study.

Primary Outcome Measure

Adverse events (AE) [ Time Frame: From the first day of medication to 30 days after the last dose] ]

Central Contacts

Related Studies